Previous studies have confirmed [8, 9] that QHF can significantly reduce the serum levels of ALT and AST in patients with NASH, and its mechanism is related to the reduction of NF-κB expression. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.